Debamestrocel clinical trials
Also written NurOwn.
How each study uses debamestrocel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the debamestrocel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Brainstorm-Cell Therapeutics (4)
Studies
Open first, then newest update. How each study uses debamestrocel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)Not yet recruitingPhase 3Brainstorm-Cell TherapeuticsNCT06973629Written as Debamestrocel - MSC-NTF (NurOwn)
- Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALSCompletedPhase 2Brainstorm-Cell TherapeuticsNCT02017912Written as Nurown MSC-NTF cells
- Safety and Efficacy of Repeated Administrations of NurOwn® in ALS PatientsCompletedPhase 3Brainstorm-Cell TherapeuticsNCT03280056Written as NurOwn® (MSC-NTF cells)
- Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MSCompletedPhase 2Brainstorm-Cell TherapeuticsNCT03799718Written as NurOwn (MSC-NTF cells)
Codes
What other systems call debamestrocel · ClinicalTrials.gg INT016690
- UNII (FDA) GPC34QP6X6DEBAMESTROCELOne source FDA
- NCI Thesaurus C190756DebamestrocelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | GPC34QP6X6 | DEBAMESTROCEL | One source FDA |
| NCI Thesaurus | C190756 | Debamestrocel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.